Generate Investment Management Ltd Invests $7.47 Million in Thermo Fisher Scientific Inc. $TMO

Generate Investment Management Ltd acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 15,403 shares of the medical research company’s stock, valued at approximately $7,471,000.

A number of other institutional investors and hedge funds also recently modified their holdings of TMO. Norges Bank acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at approximately $2,264,615,000. Soundwatch Capital LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at $807,713,000. Flossbach Von Storch SE increased its holdings in shares of Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after acquiring an additional 1,314,182 shares during the period. EdgePoint Investment Group Inc. lifted its position in Thermo Fisher Scientific by 282.5% in the 2nd quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock valued at $536,450,000 after purchasing an additional 977,127 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Thermo Fisher Scientific by 58.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,293,264 shares of the medical research company’s stock worth $929,828,000 after purchasing an additional 843,267 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $583.52 on Wednesday. The stock has a market capitalization of $219.23 billion, a P/E ratio of 33.71, a P/E/G ratio of 4.16 and a beta of 0.90. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The firm’s 50 day moving average is $575.23 and its 200-day moving average is $506.59.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Insider Activity at Thermo Fisher Scientific

In related news, COO Michel Lagarde sold 22,046 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the completion of the transaction, the chief operating officer owned 84,117 shares of the company’s stock, valued at approximately $47,404,976.52. This trade represents a 20.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Frederick M. Lowery sold 6,912 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total value of $4,022,369.28. Following the completion of the sale, the executive vice president owned 14,367 shares of the company’s stock, valued at $8,360,731.98. The trade was a 32.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 149,271 shares of company stock valued at $86,507,282. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on TMO shares. Citigroup upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $580.00 to $660.00 in a research report on Thursday, December 11th. Argus increased their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $616.60.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.